Bromopride

Summary

Bromopride (CHEMBL399510) is a phase-3 clinical-stage small molecule (ATC A03FA04); indicated across 2 conditions including dyspepsia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A03FA04
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 344.25 Da · C14H22BrN3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL399510
Name	Bromopride
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	2446
ATC	A03FA04
Molecular formula	C14H22BrN3O2
Molecular weight	344.25
InChIKey	GIYAQDDTCWHPPL-UHFFFAOYSA-N

SMILES: CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Br

IUPAC name: 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide

Also known as: Bromoprida, Bromopride, Movipride, NSC-758391, SID11112553, SID56463076, SID104171315, BROMOPRIDE, SID144204094, SID170466299, bromopride

Patent coverage: 732 distinct patent families (3,245 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Alpha-2A adrenergic receptor, Beta-lactamase, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 1A, Acetylcholinesterase, Prostaglandin G/H synthase 1, D(3) dopamine receptor, Cytochrome P450 2D6, Cytochrome P450 1A2.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 10 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD3	7.87	AC50	13.6	nM	CHEMBL_ACT_25195109
HTR1A	5.41	AC50	3860	nM	CHEMBL_ACT_25165629
ADRA2A	5.31	AC50	4889	nM	CHEMBL_ACT_25157034
CYP2D6	5.3	Potency	5012	nM	CHEMBL_ACT_5010671
CYP2D6	5.3	AC50	5012	nM	CHEMBL_ACT_6037409
DRD1	5.12	AC50	7499	nM	CHEMBL_ACT_25115815
P00811	5.1	Potency	7943	nM	CHEMBL_ACT_4687472
CYP1A2	5	AC50	10000	nM	CHEMBL_ACT_6034224

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
dyspepsia	3	MONDO:0002268	EFO:0008533

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02604576	PHASE3	COMPLETED	Efficacy of Bromopride and Simethicone Versus Bromopride in Functional Dyspepsia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).